Abortion Pill Distribution Limited Following Court Ruling
A significant change has occurred in the way abortion services are provided in the United States. A federal appeals court has imposed significant restrictions on the distribution of mifepristone, an abortion-inducing drug, by prohibiting its mailing.
The court ruling mandates that mifepristone can only be distributed in person at clinics, effectively overruling previous regulations set by the primary drug regulatory authority in the country. This development represents the most significant shift in US abortion policy since the landmark 2022 Supreme Court ruling that overturned Roe v. Wade and allowed states to enforce abortion bans.
Impact on Louisiana's Abortion Ban
The court decision agrees with Louisiana's argument that mailing the drug effectively nullifies the state's ban on abortion at all stages of pregnancy. The ruling states, "Every abortion facilitated by the action of the drug regulatory authority negates Louisiana's ban on medical abortions and undermines its policy that 'every unborn child is a human being from the moment of conception and is, therefore, a legal person.'"
Mifepristone has been an integral part of most abortions in the US since its approval in 2000 as a safe and effective way to end early pregnancies. It is usually used in conjunction with a second drug, misoprostol.
Abortion By Pills Becoming the Norm
Research indicates that most abortions in the U.S. are facilitated through pills and about one in four abortions nationally are prescribed via telehealth. One study of abortion providers last year suggested that more women in states where abortion is banned obtained abortions this way than by traveling to other states.
Some states with a Democratic majority have laws that aim to protect providers who prescribe via telehealth to patients in places with bans. The increased usage of abortion pills is a key reason why those opposing abortion have focused on the pills in legislation and litigation.
Unusual Overruling of Drug Regulatory Authority
It is unusual for a federal court to overrule the scientific regulations of the primary drug regulatory authority. It is unclear how quickly or completely the decision will impact the mailing of the drug throughout the country.
Historically, judges have deferred to the agency's judgments on the safety and appropriate regulation of drugs. Officials at the drug regulatory authority have repeatedly stated that the agency is conducting a new review of mifepristone’s safety.
Due to rare cases of excessive bleeding, the authority initially imposed strict limits on the prescription and distribution of the pill — it could only be prescribed by specially certified physicians and only after an in-person appointment where the person would receive the pill.
Manufacturers Criticize Court Decision
The manufacturer of generic mifepristone criticized the court’s decision, stating it “ignores the rigorous science and decades of safe use of mifepristone in a case pursued by extremist abortion opponents.”
The impact of this decision will not just be felt in states with abortion bans. Telehealth prescriptions have become common even in states where abortion is permitted — and the ruling blocks them there too.
Next Steps and Potential Supreme Court Appeal
Another mifepristone manufacturer, a defendant in the lawsuit, requested the appeals court to delay its order for one week to give the company time to “seek relief” from the Supreme Court. If the court does not grant the request, the company stated it will file an emergency appeal with the Supreme Court.
In the meantime, anti-abortion groups are celebrating the ruling. The president of a prominent pro-life organization applauded the ruling as “a huge victory for victims and survivors of reckless mail-order abortion drug regime.” She also criticized the slow pace of the review of mifepristone, stating that women and children suffer and state sovereignty is violated every day the authority allows abortion drugs to be mailed.